Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

Intensive pharmacokinetic sampling was performed in infants receiving anti tuberculosis treatment, using WHO recommended doses

Abstract

There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy, when drug disposition may differ. Intensive pharmacokinetic sampling was performed in infants routinely receiving anti tuberculosis treatment, including rifampin, isoniazid, pyrazinamide, and ethambutol, using World Health Organization-recommended doses.

Citation

Bekker, A.; Schaaf, H.S.; Draper, H.R.; van der Laan, L.; Murray, S.; Wiesner, L.; Donald, P.R.; Mcilleron, H.M.; Hesseling, A.C. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrobial Agents and Chemotherapy (2016) 60 (4) 2171-2179. [DOI: 10.1128/AAC.02600-15]

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

Published 1 January 2016